ribonucl
acid
interfer
rnai
potenti
altern
therapeut
approach
knock
overexpress
gene
sever
disord
especi
cancer
underli
genet
dysfunct
silenc
specif
gene
involv
cell
cycl
smallshort
interf
ribonucl
acid
sirna
use
clinic
sirnabas
rnai
effici
specif
safe
antisens
technolog
rnai
approach
rout
sirna
administr
sirna
therapi
depend
target
site
howev
certain
hurdl
like
poor
stabil
sirna
satur
offtarget
effect
immunogen
anatom
barrier
nontarget
deliveri
restrict
success
sirna
therapi
thu
advanc
effect
secur
longterm
deliveri
system
prerequisit
medic
util
sirna
polycation
nanocarri
mediat
target
deliveri
system
ideal
system
remov
hurdl
increas
blood
retent
time
rate
intracellular
permeabl
chapter
mainli
discuss
differ
biocompat
biodegrad
nontox
organ
inorgan
hybrid
nanocarri
encapsul
shield
sirna
differ
harsh
environ
provid
increas
system
sirna
deliveri
recent
year
one
import
transform
area
biolog
occur
rna
molecular
biolog
rna
interfer
rnai
phenomenon
firstli
discov
plant
caenorhabd
elegan
nematod
form
singlestrand
rna
ssrna
carolyn
napoli
richard
jorgensen
later
andrew
fire
craig
mello
found
rnai
doublestrand
rna
dsrna
mammalian
cell
pursu
develop
innov
therapeut
tool
biomed
field
andrew
fire
craig
mello
demonstr
dsrna
effect
downregul
gene
express
ssrna
xu
wang
fire
et
al
interfer
mechan
sirna
involv
control
mani
cellular
phenomena
includ
intranuclear
arrang
heterochromatin
develop
multipl
differenti
prolifer
cell
berezikov
core
mechan
rna
molecul
microrna
mirna
sirna
germlinedirect
piwiinteract
rna
pirna
actual
direct
degrad
proteinencod
messeng
rna
mrna
complex
certain
enzym
pirna
microrna
intrins
gener
genom
sirna
perform
exogen
design
fragment
interfer
therapi
wilson
doudna
thu
posttranscript
gene
silenc
regul
outcom
target
gene
repress
translat
sirna
sever
merit
convent
therapeut
agent
like
synthet
drug
bioflavonoid
key
advantag
remark
targetspecif
gene
knockdownsilenc
properti
lesser
side
effect
potent
gene
regul
thermodynam
stabil
eas
synthesi
low
product
cost
protein
antibodi
need
cellular
express
system
complex
protein
purif
liu
et
al
chougul
one
major
advantag
rnai
capabl
access
nondrugg
target
instanc
certain
target
protein
becom
inaccess
drug
due
alter
enzymat
function
conform
case
synthet
rna
sequenc
target
almost
desir
gene
human
genom
aagaard
rossi
advanc
associ
emerg
short
noncod
rna
stretch
known
sirna
uniqu
properti
regul
target
gene
express
invivo
invitro
current
sirna
obtain
attent
potent
therapeut
agent
sever
biolog
genet
abnorm
neurodegen
diseas
huntington
diseas
hematolog
diseas
inherit
genet
disord
domin
genet
disord
cardiovascular
disord
variou
cancer
viral
infect
autoimmun
diseas
ocular
diseas
mani
ill
caus
action
one
sever
gene
regul
via
rnai
phenomenon
gavrilov
saltzman
dorn
et
al
jagannath
wood
genet
express
may
alter
variou
genet
level
involv
rna
process
rna
stabil
chromatin
structur
chromosom
segreg
transcript
translat
carthew
sontheim
sirna
better
therapeut
agent
convent
use
therapeut
agent
effect
therapeut
therapi
first
essenti
step
ensur
deliveri
sirna
targetedsitespecif
tissu
cell
administr
site
although
system
circul
nake
rna
molecul
challeng
sever
hurdlesproblem
fast
enzymat
degrad
physiolog
biolog
media
entrap
phagocyt
extravas
blood
tumor
tissu
recognit
immun
system
renal
clearanc
poor
tissu
penetr
incompet
endocytosi
immunostimul
offtarget
effect
sever
drawback
prevent
deliveri
sirna
activ
site
lee
et
al
gewirtz
viral
nonvir
carrier
develop
carrier
system
initi
viral
vector
use
deliveri
platform
virus
deliv
therapeut
sirna
target
cell
mechan
transduct
suitabl
transient
longterm
gene
silenc
depend
type
carrier
virus
moreov
viral
vector
abil
enter
nucleu
cell
qiu
et
al
howev
convent
vector
risk
caus
immunogen
toxic
insert
mutagenesi
smaller
size
viral
particl
small
size
also
limit
size
therapeut
gene
insert
carri
carrier
conjug
variou
molecul
use
deliv
sirna
aptam
oligonucleotid
sterol
antibodi
conjug
sirna
conjug
carrier
enough
system
deliveri
sirna
therefor
overcom
associ
hurdl
system
deliveri
success
deliv
sirnabas
drug
invivo
easi
improv
extens
practic
applic
variou
carrier
vector
requir
convey
sirna
desir
site
activ
nonvir
base
biocompat
biodegrad
nontox
nanos
carrier
system
extens
employ
nanomateri
nm
compact
carrier
invivo
deliveri
sirna
nc
diameters
nm
due
small
size
nc
advanc
uniqu
physiochem
properti
micro
macro
carrier
possess
greater
ratio
surfac
area
volum
increas
number
surfaceact
molecul
nanocarri
nc
form
complex
sirna
encapsul
develop
intact
inert
molecul
particl
capabl
transfect
target
cell
induc
genet
interfer
dana
et
al
davi
et
al
show
sitespecif
transport
sirna
use
nc
human
via
system
inject
earlier
work
develop
foundat
later
research
relat
medic
applic
sirna
davi
et
al
sever
research
scientist
developedsynthes
sever
nc
cation
polymer
nanoparticl
polyplex
liposom
nanocarri
lipoplex
carbon
nanomateri
lipidbas
nanomicel
etc
nc
protect
sirna
rapid
enzymat
degrad
biolog
physiolog
media
reduc
immunogen
increas
blood
retent
time
cellular
uptak
increas
target
deliveri
advantag
respons
improv
therapeut
effect
sirna
system
circul
chapter
present
basic
mechan
sirna
interfer
advantag
variou
rout
administr
hurdleschalleng
system
deliveri
nake
sirna
overcom
hurdl
use
variou
nanocarri
sirna
interfer
intrins
process
posttranscript
gene
regul
noncod
stretch
rna
sequenc
downregul
activ
sever
code
gene
silenc
gene
express
draz
et
al
mostli
short
dsrna
fragment
known
sirna
mediat
homologybas
regul
gene
express
eukaryot
cell
fig
almeida
allshir
process
compar
anoth
approach
base
mirna
knockdown
replac
inhibit
synthet
ssrna
known
antagomirsantimir
employ
antagonist
intrins
mirna
antisens
mechan
replac
process
involv
synthet
mirna
introduc
invivo
mimic
function
endogen
mirna
rna
mimick
lead
gene
silenc
degradationinhibit
mrna
consequ
chapter
elabor
clinic
applic
rna
interfer
medic
treatment
exclus
focus
sirna
therapi
aagaard
rossi
first
step
rnai
initi
phase
involv
product
effector
molecul
two
specif
nucleotid
dou
fig
mechan
sirna
interfer
invivo
draz
et
al
blestrand
rna
molecul
approxim
base
pair
long
target
enzym
complex
known
dicer
homologydepend
mechan
cleav
recogn
mrna
rnase
iiilik
enzym
term
dicer
degrad
longer
dsrna
gener
short
interf
rna
homologydepend
mechan
gavrilov
saltzman
process
dsrna
sirna
construct
endonucleas
dicer
occur
cell
cytoplasm
format
effector
molecul
execut
phase
begin
multiprotein
complex
bound
effector
molecul
stimul
gene
silenc
sirna
bound
multisubunit
assembl
certain
protein
form
rnainduc
silenc
complex
risc
hammond
et
al
risc
complex
includ
three
protein
name
dicer
trbp
argonaut
distinct
role
dicer
join
sirna
risc
tarrna
bind
protein
trbp
assist
sirnarisc
bound
slice
protein
risc
complex
act
specif
cleavag
site
base
antisens
sirna
strand
target
mrna
molecul
aagaard
rossi
mrna
strand
almost
complementari
guid
rna
strand
recogn
slice
protein
second
instanc
complementari
sirnamrna
pair
sometim
resembl
mirna
bound
target
site
mirna
process
within
nucleu
complex
therebi
repress
translat
degrad
transcript
argonaut
ago
protein
sole
member
risc
catalyt
domain
enabl
cleavag
target
mrna
region
meister
et
al
sirna
embed
within
risc
duplex
protein
detach
remov
one
strand
risc
bound
doublestrand
sirna
refer
passeng
strand
singl
strand
known
guid
rna
remain
embed
risc
complex
fig
function
activ
complex
guid
rna
recogn
target
due
specif
intermolecular
base
pair
interact
tang
protein
compos
three
function
subunit
name
piwi
paz
mid
among
piwi
domain
possess
structur
fold
similar
rnase
h
provid
thermodynam
enthalpi
risc
complex
gavrilov
saltzman
cleavag
paz
subunit
protein
bind
two
termin
specif
connect
risc
complex
stagger
end
sirna
consist
specif
nucleotid
lie
core
domain
hydrophob
caviti
compos
variou
aromat
residu
base
termin
nucleotid
stack
song
et
al
group
sirna
bound
carboxylend
protein
middl
mid
piwi
domain
magnesium
ion
et
al
observ
argonaut
famili
also
contribut
guidestrand
select
argonaut
conserv
strand
less
thermodynam
stabl
guid
strand
cleav
anoth
one
releas
passeng
strand
schwarz
et
al
certain
basic
principl
thermodynam
stabil
sirna
end
regul
select
strand
remain
anchor
risc
complex
schwarz
et
al
strand
less
stabil
termin
usual
convert
form
mrna
molecul
recogn
later
degrad
strand
complementari
target
mrna
act
guid
rna
rnai
sever
extra
benefit
advantag
compar
other
therapeut
agent
alreadi
discuss
sect
howev
discuss
signific
advantag
sirna
detail
includ
therapeut
efficacypot
suppress
gene
express
selftargetedselect
deliveri
infect
cell
safeti
contrari
bioactiv
molecul
appli
far
includ
antisens
dna
oligonucleotid
rnaenzym
rnai
greater
potenti
antisens
technolog
bertrand
et
al
high
potenti
rnai
approach
observ
fact
effector
molecul
may
function
lower
concentr
case
ribozym
antisens
oligo
major
advantag
clinic
scenario
underli
factor
success
rnai
antisensebas
practic
treatment
purpos
autonom
target
complementari
transcript
use
host
cellular
machineri
often
lead
suppress
gene
express
much
extend
note
small
antisens
ssrna
may
also
bind
complementarili
risc
conduct
target
mrna
martinez
et
al
effici
sirna
interfer
decid
mani
paramet
structur
featur
patzel
et
al
target
mrna
access
heal
et
al
positionspecif
determin
amarzguioui
prydz
differenti
end
stabil
schwarz
et
al
import
paramet
among
thermodynam
stabil
termin
point
depend
asymmetri
hold
import
function
select
mrna
effici
usual
measur
half
maximum
inhibit
valu
known
ic
valu
high
degre
specif
sirnabas
approach
major
qualiti
enabl
recognit
target
nontarget
sequenc
basi
select
complementar
mrna
base
also
refer
watsoncrick
base
pair
interact
antisens
strand
design
base
target
mrna
sequenc
hypothet
possibl
treat
kind
genet
disord
rnai
method
know
nucleotid
sequenc
associ
gene
unlimit
capabl
antisensemedi
suppress
support
system
mutat
nearli
known
gene
protein
product
compris
human
genom
extens
rang
high
specif
may
even
permit
distinguish
abnorm
allel
gene
aris
dysfunct
nativ
allel
may
differ
singl
nucleotid
base
obvious
help
focus
predomin
mutant
exampl
case
oncogen
aagaard
rossi
furthermor
certain
malign
cancer
result
differ
etiolog
abnorm
chromosom
number
multipl
gene
mutat
epigenet
chang
clark
diseas
may
significantli
differ
case
patient
requir
person
treatment
moreov
case
respond
chemotherapi
method
due
resist
also
may
get
advantag
sirna
therapi
gottesman
rnai
effector
molecul
execut
cleav
mrna
later
stage
translat
gene
express
unlik
antisens
molecul
chanc
interact
sirna
dna
therebi
deleteri
mutat
prebirth
abnorm
due
gene
therapi
xu
wang
well
process
use
synthes
sirna
easi
cheaper
synthesi
rnai
costli
instrument
hazard
chemic
use
variou
clinic
trial
report
rnai
therapi
local
system
administr
sirna
variou
organ
kidney
eye
liver
skin
dictat
type
cell
tissu
target
site
local
deliveri
sirna
administ
specif
skin
surfac
eye
lung
etc
hand
oral
intraven
iv
intraperiton
ip
rout
system
deliveri
suitabl
genet
dysfunct
confin
particular
site
easili
amen
clinic
therapi
system
sirna
administr
mani
hurdl
less
specif
bioavail
target
site
rapid
clearanc
system
toxic
durcan
et
al
administr
local
site
turn
better
compel
option
permit
util
lower
dosag
diminish
undesir
effect
sirna
specif
administ
differ
rout
topic
gastrointestin
tract
git
respiratori
tract
nervou
system
ocular
etc
profici
administr
nake
sirna
done
topic
applic
anterior
chamber
inject
within
vitreou
posterior
chamber
particularli
local
manner
deliveri
sirna
topic
ocular
surfac
easi
compar
organ
tissu
cell
continu
progress
made
toward
use
therapeut
procedur
eye
diseas
current
certain
sirnabas
drug
topic
ocular
defect
pass
preclin
phase
variou
clinic
trial
studi
go
nguyen
et
al
b
skin
outermost
cover
bodi
largest
surfac
area
henc
prone
numer
skin
diseas
includ
genet
defect
well
dermat
rheumatoid
arthriti
psoriasi
pachyonychia
congenit
alopecia
areata
melanoma
wound
etc
topic
applic
benefici
treatment
disord
due
easi
access
affect
site
decreas
system
side
effect
elimin
firstpass
metabol
therebi
decreas
therapeut
dose
noninvas
easytoadminist
method
topic
applic
also
enhanc
patient
complianc
treatment
prausnitz
et
al
sirna
modul
tri
treatment
psoriasi
one
common
skin
disord
associ
overgrowth
keratinocyt
due
declin
apoptosi
make
plaqu
addit
inflammatori
compon
diseas
convent
treatment
psoriasi
topic
appli
corticosteroid
lead
weight
gain
itch
dryness
sting
fluid
retent
irrit
hypopigment
atrophi
hypertens
side
effect
highli
desir
find
drug
molecul
fewer
side
effect
therefor
target
genet
caus
ie
upregul
proinflammatori
cytokin
suitabl
way
treat
psoriasi
overproduct
cytokin
regul
suppress
tumor
necrosi
factor
alpha
protein
anim
studi
show
silenc
gene
encod
tumor
necrosi
factoralpha
result
improv
psoriat
lesion
anoth
success
exampl
clinic
util
sirna
drug
observ
case
allerg
contact
dermat
acd
shortterm
treatment
topic
corticosteroid
calcineurin
inhibitor
avail
earlier
howev
develop
sirna
molecul
recent
year
enabl
specif
target
genet
factor
acd
genet
character
elev
express
affect
skin
area
reduct
express
rnai
silenc
decreas
inflammatori
respons
immun
system
hypersensit
aldawsari
et
al
despit
advantag
sever
anatom
barrier
due
composit
cellular
distribut
superfici
surfac
skin
outer
stratum
corneum
imperm
therapeut
rna
act
barrier
topic
administr
madison
issu
low
penetr
overcom
use
carrier
system
deliv
encapsul
therapeut
sirna
molecul
penetr
stratum
corneum
reach
target
site
within
dermal
layer
first
carrier
system
abl
encapsul
form
complex
sirna
second
carrier
system
must
possess
abil
cross
stratum
corneum
reach
target
cell
skin
importantli
carrier
system
abl
bypass
endolysosom
degrad
reach
nucleu
obtain
clinic
impact
rnai
topic
applic
aldawsari
et
al
ophthalmolog
earliest
field
effici
rnaibas
therapeut
studi
clinic
trial
gene
therapi
proven
success
case
ocular
complex
due
certain
uniqu
properti
immunogenicallyprivileg
easili
assess
site
moreov
compar
distinct
part
rest
bodi
conley
naash
henc
low
therapeut
dose
requir
probabl
system
toxic
also
confin
within
local
area
subsequ
enabl
target
deliveri
thu
rnai
method
employ
profici
treatment
differ
visual
impair
irrevers
blind
conley
naash
sirnabas
therapi
introduc
advanc
resolv
visual
impair
result
due
agedepend
macular
degener
glaucoma
photoreceptor
degener
util
distinguish
qualiti
advanc
harm
eye
could
premis
new
medic
sick
includ
glaucoma
agerel
macular
degener
photoreceptor
degener
campochiaro
exampl
major
ophthalm
disord
human
anterior
ischem
optic
neuropathi
glaucomarel
blind
consequ
retin
ganglion
cell
rgc
destruct
effici
treat
intravitr
administr
sirna
studi
rat
model
suggest
loss
rcg
due
cleavag
nucleas
unregul
case
optic
nerv
damag
intravitr
deliveri
chemicallymodifi
synthet
sirna
inhibit
express
express
enhanc
rgc
surviv
remark
persist
exogen
deliv
sirna
longer
span
month
safer
rna
interfer
without
prompt
interferonmedi
inflamm
retin
region
immunogenicallyprivileg
contrari
convent
ophthalm
drug
formul
sometim
caus
ocular
irrit
trial
rnai
result
suppress
enzym
thu
sirna
clinic
proven
latent
neuroprotect
compon
intervent
ocular
diseas
concern
rgc
loss
ahm
et
al
despit
suitabl
site
target
sirna
releas
problem
observ
ocular
administr
first
physic
barrier
protect
viscou
fluid
secret
lacrim
gland
known
tear
film
continu
wash
appli
formul
complet
absorpt
second
hindranc
produc
conjunctiv
corneal
epitheli
cell
low
penetr
de
la
fuent
et
al
similar
hurdl
produc
bloodretin
barrier
bodor
buchwald
mention
physiolog
constraint
ocular
administr
interf
rna
suffer
low
bioavail
therefor
deliveri
rna
via
ocular
site
depend
effici
deliveri
platform
lung
vital
organ
respiratori
system
attribut
special
morpholog
featur
larg
surfac
area
vascular
structur
featur
enabl
sitespecif
administr
lung
aerosol
formul
intranas
instil
provid
novel
method
cure
respiratori
relat
diseas
thoma
et
al
also
sirna
prevent
degrad
nucleas
pulmonari
administr
respiratori
tract
howev
certain
physic
hurdl
exampl
beat
moment
cilia
flow
mucu
clearanc
respiratori
rout
epitheli
cell
neg
charg
cell
membran
surfac
gutbier
et
al
hindranc
influenc
profici
invivo
deliveri
sirna
griesenbach
et
al
numer
investig
examin
spite
troubl
scope
local
administr
sitespecif
applic
sirna
organ
respiratori
system
investig
discov
new
medic
strategi
major
respiratoryassoci
disord
exampl
influenza
respiratori
syncyti
infect
cancer
sever
acut
respiratori
syndrom
sar
atyp
mycobacteri
infect
lung
cancer
respiratori
alphaherpesviru
infect
pulmonari
fibrosi
asthma
chronic
obstruct
pulmonari
disord
copd
emphysema
respiratori
syncyti
viru
rsv
parainfluenza
viru
piv
rhinovirus
coronaviru
scv
ischem
reperfus
injuri
endogen
access
diseas
lung
confin
deliveri
peculiar
site
pulmonari
administr
done
inhal
intranas
rout
intratrach
rout
local
deliveri
sirna
lung
disord
provid
altern
system
administr
effici
suppress
target
protein
common
exampl
commerci
sirna
formul
pulmonari
administr
method
use
case
upper
respiratori
tract
infect
occur
due
growth
rsv
formul
act
n
gene
inhibit
nucleocapsid
synthesi
rsv
therebi
control
replic
rsv
nasal
passag
trachea
cystic
fibrosi
anoth
genet
disord
involv
chronic
inflamm
mediat
ikbprotein
complex
involv
transcript
regul
dna
cytokinesi
cellular
develop
protein
produc
cystic
fibrosi
tran
membran
conduct
regul
cftr
gene
epitheli
na
transport
enac
gene
found
mutat
case
cystic
fibrosi
pulmonari
sirna
deliveri
decreas
express
epitheli
na
channel
enac
gene
downregul
activ
normal
na
cl
transport
across
cell
membran
prevent
excess
mucu
releas
lumin
hydrat
pulmonari
infect
epitheli
cell
destruct
khatri
et
al
sirna
particularli
could
administ
within
gastrointestin
system
mean
endoscop
infus
treatment
infect
surfac
gi
tract
cover
layer
fluid
call
mucu
viscou
fluid
stimul
releas
rnai
formul
straightforwardli
site
activ
therebi
elimin
undesir
effect
system
toxic
adjac
tissu
organ
pellish
et
al
moreov
applic
sirna
treatment
giassoci
diseas
strategi
also
util
illustr
cours
differ
gastrointestin
infect
determin
possibl
target
rna
interfer
exampl
tumour
necrosi
factor
alpha
case
ulcer
coliti
crohn
disord
inflammatori
bowel
diseas
ibd
zhang
et
al
ibd
earlier
treat
infliximab
chimer
monoclon
antibodi
antibodi
trigger
antiantibodi
product
elicit
immun
hypersensit
contrari
local
silenc
sirna
molecul
may
trigger
immun
respons
tradit
treatment
oesophag
cancer
involv
aggress
surgic
adjuv
chemoradi
therapi
one
common
etiolog
observ
variou
type
oesophag
malign
hyperact
bclx
l
gene
respons
inhibit
apoptosi
therefor
interf
bclx
l
express
via
sirnabas
approach
oesophag
squamou
cell
cancer
line
destruct
apoptot
programm
similar
oesophag
malign
pancreat
cancer
delay
diagnosi
chemotherapi
practic
common
reason
observ
adenocarcinoma
elev
level
serinearginin
protein
kinas
srpk
led
erron
splice
premrna
caus
certain
malign
cancer
includ
pancreat
cancer
serinearginin
protein
kinas
srpk
class
protein
regulatori
role
premrna
splice
elev
express
trial
done
hay
et
al
util
sirna
block
activ
consequ
growth
pancreat
colon
cancer
cell
line
declin
apoptot
death
much
higher
compar
common
anticanc
drug
gemcitabin
cisplatin
pellish
et
al
brain
complex
organ
bodi
regard
anatomi
function
also
term
medic
therapi
due
complex
contribut
variou
type
cell
vivid
function
convent
treatment
method
prove
effect
case
neuronassoci
problem
specif
situat
therapeut
base
rnai
could
identifi
genet
basi
comprehend
cours
neural
disord
part
prognosi
later
could
evalu
remedi
capabl
target
rnai
therapi
silenc
gene
involv
neurolog
disord
exampl
pteninduc
put
kinas
target
treatment
parkinson
diseas
deng
et
al
huntington
gene
huntington
diseas
harper
et
al
purinoceptor
neuropath
pain
dorn
et
al
egfr
intracrani
tumor
boado
certain
neurodegen
diseas
alzheim
singer
et
al
amyotroph
later
ralph
et
al
dysfunct
mediat
hypoxicischem
event
could
also
treat
sirnamedi
silenc
contrari
potenti
specif
rnai
method
effici
compromis
due
highli
imperm
bloodbrain
barrier
confin
avail
rnaibas
formul
across
brain
peripher
blood
vessel
cazzin
ring
alzheim
diseas
ad
protein
misfold
disord
caus
defect
extracellular
amyloid
diseas
lead
progress
cognit
declin
memori
loss
research
found
cleav
amyloid
precursor
protein
app
key
compon
gener
sequenti
proteolyt
cleavag
event
gene
express
henc
therapeut
sirna
molecul
target
consid
potenti
gene
therapi
ad
similarli
target
decreas
app
express
mechan
also
serv
purpos
huntington
diseas
hd
anoth
neurodegen
diseas
benefit
new
sirna
modul
diseas
associ
upregul
huntingtin
htt
gene
add
extra
polyglutamin
stretch
region
htt
protein
product
mutant
protein
type
misfold
form
inclus
bodi
striat
neuron
degener
cell
type
henc
cn
sever
affect
case
hd
silenc
mutant
htt
mrna
rnai
approach
seen
clinic
util
gherardini
et
al
vagin
rout
primari
site
invas
microbi
agent
caus
infect
especi
sexual
transmit
diseas
cancer
inflammatori
problem
instanc
topic
administr
rnabas
product
ideal
approach
anticip
sexual
transmit
diseas
type
applic
provid
benefit
lower
therapeut
dose
maximum
bioavail
site
infect
rossi
therefor
studi
ongo
context
targetedsirna
therapi
use
identifi
gene
target
human
immunodefici
infect
hiv
cervic
tumor
infect
howev
usual
drawback
vagin
applic
patient
complianc
hiv
one
initi
viral
diseas
target
rnai
effect
treat
viral
infect
well
apart
genet
disord
sirna
molecul
develop
target
differ
viral
gene
includ
gag
tat
nef
vif
rev
env
involv
viral
cycl
hiv
rna
may
also
act
host
cellular
cofactor
nfkb
well
revers
transcriptas
control
hiv
replic
effect
vagin
administr
success
case
cervic
cancer
result
due
overexpress
hpv
oncogen
trigger
unregul
prolifer
cell
therefor
inhibit
activ
hpv
gene
via
sirna
effect
slow
prolifer
cancer
cervic
cell
sirna
therapi
specif
target
human
hpv
gene
signific
effect
stop
multipl
cervic
tumor
compar
system
deliveri
suitabl
clinic
situat
bloodborn
disord
malign
thu
recent
research
focus
altern
bring
system
deliveri
sirna
effici
safe
procedur
gene
silenc
chapter
discuss
role
nc
overcom
pitfal
system
sirna
administr
variou
nanoparticl
use
nonvir
vector
facilit
deliveri
rather
nake
sirna
molecul
oral
rout
ideal
mode
administr
due
patient
complianc
moreov
benefit
costeffect
facil
administr
oral
rout
attract
attent
drug
deliveri
also
prefer
local
administr
intestin
therapeut
acid
environ
stomach
readili
degrad
nake
oligonucleotid
therefor
stabl
administr
via
oral
rout
achiev
nano
carriermedi
deliveri
akhtar
although
iv
administr
success
mode
administr
mani
drug
formul
observ
deliveri
sirna
method
hamper
short
lifespan
kidney
filtrat
serum
protein
aggreg
enzymat
degrad
therapeut
rna
inject
exhibit
mice
rat
human
primat
bare
sirna
rapidli
clear
bodi
circul
iv
infus
halflif
short
minut
approxim
h
also
larg
accumul
therapeut
oligonucleotid
occur
kidney
iv
administr
huang
et
al
addit
less
stabil
therapeut
rna
administ
iv
rout
common
aftereffect
repeat
iv
administr
phlebiti
loss
vein
risk
embol
regard
ip
deliveri
provid
better
option
especi
case
cancer
ovari
digest
system
peritoneum
ip
administr
moreov
found
enhanc
invivo
stabil
sirna
enabl
administr
larg
volum
formul
low
concentr
avoid
particl
aggreg
singhania
et
al
mani
malign
tumor
aris
stimul
nuclear
factorkappa
b
nfkb
instanc
gastric
tumor
show
poor
prognosi
resist
chemotherapi
alon
thu
nfkb
common
target
rna
silenc
studi
demonstr
effici
intraperiton
administr
nfkb
sirna
along
common
chemotherapeut
agent
paclitaxel
treat
periton
prevail
gastric
tumor
lower
express
nfkb
express
observ
western
blot
analysi
apoptot
destruct
cell
transfect
nfkb
sirna
compar
treatment
paclitaxel
alon
inou
et
al
efficaci
rna
interfer
may
differ
variou
sirna
oligonucleotid
target
mrna
sequenc
distinct
nucleotid
full
effici
sirna
obtain
deliv
sirna
reach
action
site
without
distort
mammalian
cell
success
perform
cleav
action
naito
uitei
even
though
approxim
arbitrari
sirna
nonspecif
sequenc
mediat
mrna
silenc
efficaci
half
profici
profici
account
nonspecif
sirna
oligonucleotid
chalk
et
al
decreas
efficaci
sirna
may
mani
caus
includ
instabl
unspecif
target
diseasedcel
competit
endogen
rna
satur
rnaimirna
complex
immun
respons
activ
offtarget
impact
problem
becom
promin
appli
system
mode
administr
deliv
sirna
impos
disadvantag
compar
local
administr
main
problem
conserv
activ
sirna
circul
system
blood
vessel
system
circul
sirna
hinder
due
mani
anatom
physiolog
protect
barrier
present
human
bodi
renal
filtrat
vascular
endothelium
extracellular
matrix
serum
protein
aggreg
cellular
intern
phagocyt
uptak
endosom
degrad
risc
load
sirna
need
overcom
barrier
reach
site
action
exhibit
clinic
signific
impact
consider
profici
rnai
mediat
gene
silenc
stimul
either
direct
indirect
mechan
first
involv
rnamedi
process
exogen
synthet
sirna
make
complex
pair
long
duplex
effector
molecul
target
toward
specif
cell
meanwhil
second
approach
involv
endogen
mirnabas
strategi
longer
rna
hairpin
transcript
process
intracellularli
produc
effector
sirna
direct
method
straightforward
effici
gene
cleavag
impact
extern
introduc
synthet
directli
gener
sirna
short
term
thu
synthet
sirna
requir
administ
repeatedli
dose
expens
timeconsum
mirnabas
rnai
drug
contrari
show
high
stabil
longtim
effect
henc
singl
treatment
enough
effect
gene
therapi
aagaard
rossi
anoth
great
pitfal
sirna
relat
invivo
stabil
expos
sirna
liabl
hydrolysi
extracellular
compart
due
action
variou
enzym
present
serum
target
tissu
halflif
nake
sirna
serum
report
far
sever
minut
hour
rettig
behlk
sirna
molecul
structur
contain
ribos
sugar
backbon
contrari
hydrogen
atom
dna
hydroxyl
group
posit
pentos
ring
target
serum
nucleas
czech
et
al
nucleas
break
phosphodiest
backbon
rna
degrad
nucleic
acid
thu
challeng
deliv
intact
sirna
conserv
therapeut
activ
circul
meanwhil
sirna
must
surviv
serum
also
reach
target
cell
specif
tissu
intern
occur
appropri
achiev
requir
rnai
effect
guo
et
al
sirna
administ
introduc
system
circul
rout
toward
site
action
obscur
mani
structur
anatom
defens
barrier
fig
step
clearanc
kidney
reticuloendotheli
system
re
organ
lung
liver
bone
marrow
spleen
primari
obstruct
entrap
particl
diamet
larger
nm
thu
ideal
rna
molecul
bypass
renal
re
clearanc
diamet
rang
nm
approxim
addit
therapeut
materi
within
size
rang
show
enhanc
uptak
tumor
site
passiv
leaki
capillari
pore
size
nm
song
et
al
pass
re
sirna
enter
target
tissu
hinder
local
barrier
present
extracellular
matrix
layer
endotheli
cell
typic
endotheli
line
tissu
pore
size
nm
henc
smallest
pore
allow
particl
nm
rettig
behlk
circumst
nake
sirna
molecul
one
conjug
small
molecular
ligand
easili
penetr
endotheli
cell
also
nake
complex
sirna
must
squeez
dens
extracellular
space
reach
surfac
target
cell
even
bypass
nucleas
activ
serum
extracellular
matrix
rnai
pathway
still
hinder
variou
obstacl
reach
proxim
target
cell
uptak
sirna
target
cell
also
crucial
prior
therapeut
rna
perform
gene
silenc
function
expos
sirna
molecul
neg
charg
larg
constrain
passag
cell
membran
anticip
aggreg
insid
cell
second
barrier
overcom
endolysosom
compart
within
cytoplasm
space
vesicl
also
contain
variou
intracellular
rnaas
may
degrad
sirna
molecul
intern
ie
endosom
engulf
strategi
wang
et
al
design
deliv
sirna
therefor
essenti
enabl
endocytosi
subsequ
endosom
escap
sirna
molecul
addit
sirna
suscept
hydrolysi
endosom
nucleas
enzym
incorpor
risc
improv
efficaci
compel
clinic
util
gavrilov
saltzman
recent
studi
conduct
birmingham
et
al
mouldi
wilson
doudna
shown
specif
rnai
sometim
compromis
evid
studi
show
sirna
molecul
probabl
specif
presum
sirna
treatment
bring
offtarget
gene
silenc
offtarget
effect
refer
suppress
genet
region
caus
gene
target
phenomenon
may
produc
undesir
genet
alter
cellular
dysfunct
common
reason
offtarget
silenc
seed
region
sirna
sequenc
region
character
partial
homolog
nucleotid
long
sequenc
particularli
insid
untransl
sequenc
bound
differ
mrna
rather
desir
target
mrna
birmingham
et
al
condit
seed
region
sirna
acquir
complementar
certain
regulatori
mirna
may
distort
gene
express
mouldi
moreov
failur
discrimin
guid
strand
passeng
strand
risc
may
prompt
chanc
complementari
interact
sirna
nontarget
mrna
offtarget
effect
also
aris
effect
immun
activ
rna
perceiv
immunoreceptor
sometim
tolllik
receptor
tlr
trigger
signal
biomolecul
cytokin
may
alter
gene
express
wilson
doudna
offtarget
cleavag
ca
nt
overlook
prompt
advers
mutat
genet
level
result
unexpect
consequ
thu
select
sequenc
candid
sirna
done
specif
two
basic
process
follow
determin
potent
rnai
sequenc
specif
target
gene
predict
bioinformat
approach
implement
initi
stage
sirna
develop
suitabl
sequenc
sirna
molecul
later
exclus
trial
potent
therapeut
sirna
sequenc
perform
observ
normal
protein
express
profil
inadvert
offtarget
effect
may
result
abnorm
interpret
data
potenti
toxic
bioactiv
materi
usual
analogu
cellular
biomolecul
work
similarli
invivo
biomolecul
extern
deliv
therapeut
sirna
almost
resembl
intrins
sirna
depend
endogen
machineri
induc
rna
interfer
henc
signific
risk
satur
pathway
henc
disturb
nativ
biolog
system
base
cellular
process
execut
role
gener
activ
immun
mechan
serv
defenc
mechan
advantag
howev
sometim
evok
undesir
immun
sensit
may
lead
advers
effect
marqu
william
sirna
might
discrimin
foreign
particl
variou
defenc
mechan
compon
immun
system
exampl
sirna
may
recogn
cytoplasm
endosom
tolllik
receptor
express
surfac
differ
immunocompet
cell
consequ
releas
cytokin
typei
interferon
gener
inflammatori
reaction
immun
stimul
properti
sirna
directli
relat
size
sirna
oligonucleotid
base
pair
usual
nt
confer
cytotox
cell
could
safe
transfect
bp
longer
dsdna
without
cellular
toxic
contrari
longer
rna
strand
elicit
immun
respons
bound
either
tlr
certain
enzym
synthetasernas
l
protein
kinas
trigger
interferon
specif
gurich
motif
actual
determin
refer
danger
motif
exampl
endosom
vesicl
plasmacytoid
dendrit
cell
sequenc
recogn
stimul
innat
mechan
releas
inflammatori
cytokin
anoth
exampl
activ
counter
cpg
motif
antisens
oligonucleotid
thu
immun
action
control
mode
deliveri
passag
across
variou
intracellular
compart
sirna
rna
oligonucleotid
larger
base
pair
highli
potent
dicer
substrat
sirna
need
safe
administ
monitor
immunogen
sideeffect
rose
et
al
overcom
abovediscuss
therapeut
hurdl
achiev
effici
potent
system
deliveri
unstabl
sirna
sever
method
develop
increas
stabil
serum
improv
invivo
deliveri
efficaci
gene
silenc
tendenc
even
though
abovement
method
sever
advantag
provid
good
platform
improv
deliveri
nake
sirna
howev
frequent
applic
method
limit
also
numer
drawback
safeti
issu
insert
mutagenesi
immunogen
low
load
effici
laboratorysmallscal
product
furthermor
sirna
liabl
nucleas
degrad
circular
plasmid
therefor
need
stabl
deliveri
system
improv
system
deliveri
sirna
day
altern
approach
synthesi
nonvir
vector
synthet
carrier
inflow
resolv
reduc
drawback
enhanc
invivo
sirna
deliveri
nonvir
vector
variou
size
shape
dimens
consist
differ
biocompat
biodegrad
materi
carrier
load
entrap
high
amount
sirna
shield
variou
hurdl
barrier
rapid
elimin
enzymat
degrad
reduc
potenc
invitro
invivo
etc
current
differ
dimens
shape
nanos
least
one
dimens
nm
nonvir
vector
appli
system
deliveri
gene
drug
codeliveri
gene
drug
togeth
nanos
nonvir
vector
enhanc
pharmacokinet
increas
halflif
epr
enhanc
permeabl
retent
effect
decreas
rapid
renal
filtrationclear
protect
extracellular
enzymat
degrad
support
escap
endosom
intracellular
nc
benefici
properti
like
high
biocompat
nonimmunogen
etc
polym
lipidbas
nanomicel
liposom
dendrim
mostli
use
nonvir
nc
size
nake
sirna
length
hansen
et
al
smith
et
al
nm
diamet
sinden
et
al
molecular
weight
kda
whitehead
et
al
kidney
made
numer
glomeruli
main
function
glomeruli
natur
filtrat
barrier
undesir
byproduct
blood
size
pore
glomeruli
membran
approxim
nm
wartiovaara
et
al
molecul
molecular
weight
size
kda
nm
respect
typic
rapidli
expel
kidney
rappaport
et
al
system
deliveri
sirna
rapidli
expel
bodi
system
either
renal
clearanc
filtrat
renal
system
entrap
re
liver
spleen
lung
bone
marrow
increas
retent
time
sirna
bodi
sirna
entrap
indiffer
nc
size
rang
nm
diamet
optim
size
rang
help
avoid
potenc
avoid
renal
clearanc
re
entrap
allow
nc
remain
circul
longer
period
increas
rate
intracellular
penetr
tumor
cell
tissu
via
passiv
target
jang
et
al
pecot
et
al
specif
physiochem
properti
nake
sirna
anion
charg
due
presenc
phosphat
group
structur
hydrophil
plasma
membran
made
lipid
bilay
lipophil
natur
anion
charg
therefor
intracellular
penetr
sirna
across
plasma
membran
quit
limit
passiv
transport
due
electrostat
repuls
sirna
administr
bloodstream
immedi
cover
major
compon
blood
plasma
protein
ie
serum
albumin
initi
immun
system
engulf
albumin
coat
sirna
phagocyt
nc
entrap
cover
sirna
avoid
engulf
phagocyt
cell
increas
cell
penetr
sirna
polycation
posit
charg
nc
best
suit
high
sirna
load
shield
degrad
bloodstream
circul
system
deliveri
sirna
especi
metastat
tumor
commonli
use
polym
polyethyleneimin
pei
illum
davi
norman
et
al
accord
bonnet
et
al
linear
peisirna
lpeisirna
conjug
show
better
cytocompat
nonimmunogen
branch
peisirna
bpeisirna
conjug
bonnet
et
al
howev
nc
prepar
singl
pei
polym
stabl
system
deliveri
sirna
agglomer
bloodstream
due
slat
medium
serum
protein
promin
solut
overcom
problem
use
copolymermix
polym
di
triblock
copolym
stabl
exampl
pei
mix
poli
ethylen
glycol
peg
prepar
pegyl
peisirna
peg
polym
cover
outsid
peisirna
conjug
form
hydrophil
layer
suffici
reduc
agglomer
tendenc
nc
increas
epr
effect
malek
et
al
merkel
et
al
kim
et
al
prepar
mannosyl
pegyl
polyethyleneiminesirna
peipegmansirna
polyplex
nc
approxim
size
nm
increas
cellular
uptak
sirna
conjug
pei
entrap
high
amount
neg
charg
sirna
peg
provid
outer
stabl
hydrophil
membran
mannos
use
cell
bind
ligand
macrophag
kim
et
al
polycation
peptid
like
polyhistidin
polym
lipid
nc
also
use
system
improv
deliveri
sirna
midoux
et
al
although
entrap
sirna
differ
posit
charg
nc
enhanc
therapeut
efficaci
sirna
deliveri
system
enough
deliv
high
amount
sirna
specifi
tissuescel
passiv
diffus
transport
due
nc
capabl
differenti
infect
cancer
cell
normal
healthi
cell
also
posit
charg
nc
agglomer
differ
cell
media
biolog
fluid
increas
concentr
sirna
target
site
nanocarriersmedi
target
deliveri
system
new
novel
approach
increas
therapeut
efficaci
sirna
receptormedi
endocytosi
activ
transport
system
improv
rate
cellular
uptak
sirna
load
nc
activ
target
transport
system
achiev
surfac
modif
nc
use
differ
target
ligand
specif
ligand
bind
sitespecif
receptor
overexpress
target
cell
tissu
akinc
et
al
exampl
commonli
use
ligand
poli
saccharid
vitamin
duan
et
al
antibodi
gu
et
al
peptid
aptam
transferrin
tf
etc
develop
phsensit
nc
commonli
use
approach
improv
deliveri
sirna
system
administr
especi
cancer
ph
blood
extracellular
matrix
fluid
mildli
basic
ph
wherea
ph
intracellular
compart
howev
cancer
cell
even
acid
ph
extracellularli
intracellularli
caus
higher
rate
glycolysi
tendenc
produc
higher
co
lactic
acid
high
lactat
level
indic
metastas
tumor
recurr
prognosi
cancer
patient
basic
three
differ
materi
use
develop
phsensit
nc
protoniz
acidlabil
destabil
compound
torchilin
sawant
torchilin
poli
diisopropylamino
ethyl
methacryl
pdpa
smart
polym
use
form
nc
nc
bypass
endosom
compart
improv
efficaci
sirna
deliveri
qian
berkland
phsensit
polym
hydrophob
natur
neutral
physiolog
ph
medium
howev
mild
acid
medium
ph
chang
hydrophob
hydrophil
natur
licciardi
et
al
polym
easili
encapsul
desir
amount
sirna
shield
sirna
enzymat
degrad
physiolog
ph
encapsul
sirna
releas
cytoplasm
dissoci
nc
earli
endosom
lysosom
ph
via
proton
pdpa
display
outstand
proton
spong
effect
pse
due
tertiari
amin
termin
surfac
yu
et
al
numer
nc
develop
stabl
blood
ph
give
protect
sirna
circul
bloodstream
degrad
low
ph
tumor
tissu
environ
releas
sirna
kim
et
al
pse
effect
use
protect
degrad
therapeut
agent
load
nc
differ
cell
organel
earli
endosom
lysosom
use
variou
amin
polym
like
pdpa
pei
benjaminsen
et
al
polyllysin
pll
etc
polym
destroy
cell
organel
upon
acidif
low
acid
ph
safe
deliv
genet
materi
nucleu
pse
produc
numer
slightli
basic
cojug
ph
promot
proton
h
absorpt
cellular
organel
lower
ph
osmot
pressur
gener
around
organel
membran
due
gener
osmot
pressur
acid
endosom
burst
releas
materi
cytoplasm
advantag
pse
could
easili
control
effect
partial
alter
group
carboxyl
acid
cooh
tertiari
amin
whenev
function
group
attach
surfac
nc
form
electrostat
steric
interact
extrem
reactiv
acid
organel
sirna
appropri
attach
cellular
entri
yezhelyev
et
al
discuss
earlier
nake
sirna
effici
across
plasma
membran
due
unfavor
physicochem
properti
sirna
less
amount
sirna
pass
semiperm
plasma
membran
intracellular
deliveri
sirna
less
stabl
bloodstream
less
halflif
min
due
rapid
enzymat
degrad
endogen
serum
nucleas
tseng
et
al
intracellular
traffick
sirna
start
earli
endosom
vesicl
sirna
fuse
sort
endosom
final
transfer
content
late
endosom
high
amount
sirna
entrap
late
endosom
lysosom
less
amount
sirna
reach
cytoplasm
come
play
regardless
releas
mechan
avoid
rapid
degrad
shield
engulf
late
endosom
lysosom
variou
nc
develop
shield
nake
sirna
cation
lipid
lu
et
al
polym
di
triblock
copolym
nc
qian
berkland
nanomicel
zhou
et
al
etc
nc
appli
shield
improv
invitro
invivo
deliveri
sirna
must
safe
nontox
human
health
come
direct
contact
human
natur
obtain
molecul
safer
compar
chemic
synthes
molecul
synthesi
nc
sever
hard
acid
base
other
hazard
chemic
use
acid
hazard
chemic
give
sever
toxic
effect
human
health
environ
also
mostli
nc
diamet
nm
howev
long
chain
polymer
nc
diamet
nm
nc
develop
system
deliveri
sirna
broadli
classifi
three
differ
type
organ
nanocarri
onc
prepar
natur
synthet
organ
molecul
mixtur
onc
typic
soft
biocompat
biodegrad
less
toxic
nonimmunogen
highli
stabl
shield
sirna
last
decad
sever
scientist
research
alreadi
use
numer
organ
nc
protect
drug
nucleic
acid
harsh
environ
enzymat
degrad
blood
plasma
protein
system
circul
insid
bodi
commonli
use
onc
nanomicel
liposom
polymer
nanoparticl
dendrim
carbon
nanomateri
graphen
oxid
sheet
nanotub
spheric
shape
fulleren
nc
addit
benefit
synthesi
procedur
onc
quit
easi
encapsul
drug
nucleic
acid
molecul
control
deliveri
surfac
onc
simpli
decor
target
biomolecul
develop
target
carrier
system
advantag
make
onc
appeal
system
drug
gene
deliveri
biomed
applic
current
sever
natur
synthet
polymer
nanocarri
pnc
fig
offer
great
platform
deliv
drug
gene
improv
efficaci
polym
highli
biocompat
biodegrad
nontox
natur
outstand
control
releas
charact
gener
pnc
cation
anion
nonion
natur
polycation
polym
emerg
one
promis
candid
develop
effici
gene
deliveri
vector
polym
broadli
classifi
twotyp
base
sourc
natur
synthet
commonli
use
natur
polym
chitosan
cs
poli
lactic
acidcoglycol
acid
plga
zhou
et
al
atelocollagen
minakuchi
et
al
inulin
cavallaro
et
al
cs
linear
natur
cation
fda
food
drug
administr
approv
polysaccharid
long
chain
monosaccharid
carbohydr
coblock
polym
glucosamin
nacetyl
glucosamin
polym
use
invitro
invivo
system
deliveri
sirna
nontox
biocompat
biodegrad
properti
malhotra
et
al
vauthier
et
al
current
cs
highli
use
polysaccharid
polym
deliv
therapeut
agent
drug
genet
agent
due
high
permeabl
capabl
across
semiperm
cell
membran
de
rieux
et
al
one
studi
prepar
novel
amino
acidfunction
argglyasp
rgd
chitosan
nanoparticl
rgdchnp
significantli
increas
select
intratumor
deliveri
sirna
regul
mani
growthpromot
gene
fak
postn
accompani
therapeut
efficaci
orthotop
anim
studi
ovarian
cancer
model
han
et
al
besid
natur
polym
sever
biocompat
biodegrad
nontox
synthet
pnc
also
use
system
deliveri
sirna
pll
cun
et
al
pei
nimesh
chandra
peg
dimethylamino
ethyl
methacryl
polyfluoren
cyclodextrinbas
polyc
polym
linear
branch
similarli
effici
way
shield
effici
deliveri
sirna
type
pnc
encapsul
high
amount
sirna
deliv
via
passiv
rout
increas
deliveri
concentr
sirna
specif
infect
cellstissu
escap
normal
cell
tissu
differ
activ
target
molecul
attach
surfac
pnc
tabl
term
micel
given
mcbain
micel
form
supramolecular
selfassembl
surfact
lipid
aqueou
insolubl
polym
euliss
et
al
amphiphil
molecul
molecul
hydrophob
nonpolar
tail
one
end
hydrophil
polar
head
end
fig
micel
colloid
suspens
amphiphil
molecul
amphiphil
molecul
mix
aqueou
medium
nonpolar
hydrophob
tail
arrang
insid
molecul
let
polar
side
ie
head
remain
outer
side
direct
contact
aqueou
medium
hollow
spheric
cylindr
structur
form
process
self
assembl
exampl
cao
et
al
mix
cation
pcl
pei
selfassembl
form
biodegrad
micel
micel
util
carri
antiapoptot
specif
sirna
along
anticanc
drug
docetaxel
dox
folic
acid
surfaceconjug
target
ligand
hepat
cancer
cell
nanoassembl
simultan
deliv
drug
sirna
yield
combin
rnaichemotherapeut
benefit
hepat
cancer
cao
et
al
similarli
zhu
et
al
synthes
pegpppeip
nanomicel
deliveri
sirna
survivin
gfp
along
paclitaxel
ptx
effici
downregul
gfp
gene
survivin
observ
ptxresist
nonsmal
cell
lung
cancer
cell
micellesmedi
sirna
deliveri
compar
free
drug
zhu
et
al
anoth
studi
prepar
pegyl
peisirna
micellar
nanoparticl
shown
high
entrap
effici
longterm
blood
circul
sirna
load
nanoparticl
reduc
aggreg
opson
inflamm
respons
studi
polycation
pei
use
high
load
capac
neg
charg
sirna
peg
use
other
advantag
wu
et
al
tabl
carbon
nanomateri
cnm
synthes
allotrop
carbon
graphen
graphen
oxid
go
nanotub
fulleren
exampl
studi
conduct
varkouhi
et
al
carbon
nanotub
function
pei
pyridinium
explor
sirna
deliveri
function
cation
cnt
complex
anion
sirna
provid
silenc
effici
cytotox
varkouhi
et
al
anoth
studi
ren
et
al
done
prepar
character
gobas
carrier
surfacefunction
pll
argglyasps
oligonucleotid
activ
target
tumor
nanocarri
use
load
vegfsirna
observ
perform
slow
sustain
releas
sirna
along
low
toxic
compar
bare
go
figur
show
twodimension
sheetlik
go
structur
numer
oxygen
group
like
carboxyl
acid
hydroxyl
epoxi
alkoxi
edg
side
surfac
averag
thick
go
nm
length
width
nm
depend
biomed
applic
go
high
surfac
area
capabl
hold
molecul
side
sheet
due
go
high
load
capac
carbon
nanotub
cnt
hollow
onedimens
nanostructur
cnt
may
cylindr
tubular
needl
shape
depend
number
layer
wall
cnt
threetyp
singlewal
carbon
nanotub
swcnt
doublewal
carbon
nanotub
dwcnt
multiwal
carbon
nanotub
mwcnt
typic
thick
swcnt
nm
dwcnt
nm
schedin
et
al
bae
et
al
mwcnt
nm
thick
bartelmess
et
al
nm
length
fulleren
zerodimension
footbal
like
hollow
structur
diamet
nm
fulleren
differ
number
carbon
atom
structur
like
c
c
etc
c
commonli
use
fulleren
carbon
structur
compos
hexagon
ring
pentagon
ring
call
buckybal
pristin
cnm
less
biocompat
less
sirna
load
capac
due
electrostat
repuls
cnm
modifi
coat
sever
cation
polym
like
peg
pei
chitosan
pah
poli
allylamin
hydrochlorid
plga
poli
lactic
acidcoglycol
acid
frequent
use
polym
modif
coat
polym
cnm
hold
high
concentr
sirna
due
simpl
electrostat
attract
improv
deliveri
sirna
polym
coat
cnm
modifi
suitabl
ligand
tabl
liposom
wellord
selfassembl
vesicl
amphiphil
lipid
molecul
form
minut
spheric
shape
nanoparticl
singlelamellar
multilamellar
lipid
bilay
structur
phospholipid
molecul
aqueou
medium
insid
use
encapsul
deliv
drug
genet
materi
cell
fig
akbarzadeh
et
al
liposom
highli
biocompat
biodegrad
small
size
vesicl
amphiphil
lipid
high
surfac
areatovolum
ratio
superior
physiochem
properti
like
increas
rate
biolog
membran
permeabl
flexibl
function
tune
surfac
charg
properti
make
liposom
better
nanoformul
deliv
drug
gene
other
nc
also
success
appli
clinic
hatakeyama
et
al
polycation
liposom
build
block
entrap
neg
charg
sirna
electrostat
interact
form
lipid
complex
system
call
lipoplex
wolff
rozema
far
mani
liposom
formul
got
fda
approv
mani
current
develop
clinic
trial
enabl
featur
stabl
circul
tumorspecif
target
version
sirnaliposom
carrier
nobl
et
al
drummond
et
al
patil
jadhav
liposom
nc
divid
four
main
type
base
physic
structuresnucleicacidlipid
particl
lipoplex
lipopolyplex
membranecor
nanoparticl
lipoplex
compos
sever
bilay
lipid
spheric
form
sirna
entrap
consecut
lipid
bilay
stabl
nucleicacidlipid
particl
outer
surfac
almost
neutral
inner
surfac
highli
posit
charg
due
inner
posit
charg
sirna
entrap
interior
liposom
phsensit
lipid
synthes
type
liposom
liposom
show
cation
behaviour
acid
ph
noionic
behaviour
neutral
ph
lipopolyplex
synthes
coat
liposom
opposit
charg
polym
lipid
nc
cation
charg
coat
anion
charg
polym
vice
versa
membran
core
nc
differ
structur
liposom
nc
type
nc
similar
coreshelllik
entiti
singl
multipl
inorgan
np
embed
core
surround
lipid
bilay
form
outer
shell
xia
et
al
landen
et
al
sirna
encapsul
dopc
neutral
lipid
lipid
nc
nc
decor
oncoprotein
target
ligand
improv
system
sirna
deliveri
liposom
nc
test
two
differ
orthotop
mous
model
ovarian
malign
cell
type
nc
significantli
reduc
tumor
growth
compar
nonsilenc
sirna
whenev
paclitaxel
also
load
nc
conjug
cancer
cell
growth
drastic
decreas
comparison
individu
chemotherapi
paclitaxel
rnai
therapi
nonsilenc
sirna
landen
et
al
dendrim
nanos
spheric
monodispers
highli
branch
threedimension
synthet
macromolecul
typic
dendrim
molecul
compos
three
structur
region
innermost
core
compris
atom
molecular
entiti
least
two
ident
function
group
branch
gener
inner
caviti
specif
function
group
present
surfac
fig
verma
et
al
pooja
et
al
numer
function
group
cooh
oh
suitabl
attach
variou
ligand
make
suitabl
target
deliveri
therapeut
agent
dendrim
made
repeat
branch
unit
form
shell
either
group
differ
group
shell
known
gener
g
kulhari
et
al
mix
dendrim
known
dendriplex
present
dendrim
use
deliveri
sever
hydrophob
hydrophil
drug
gene
bioimag
agent
tabl
depend
type
central
atom
differ
class
dendrim
avail
pamam
polyamidoamin
ppi
poli
propylen
imin
pll
poli
hydroxymethyl
propion
acid
etc
svenson
tomalia
due
branch
structur
sever
voidsspac
form
drug
nucleic
acid
recent
treat
cancer
research
develop
tumor
microenvironmentsensit
polypeptidesamphiphil
dendrim
carrier
sirnapaclitaxel
tmspadenssirnaptx
complex
robust
codeliveri
therapeut
agent
complex
sirna
paclitaxel
encapsul
within
hydrophil
centr
intern
hydrophob
layer
respect
outer
peg
layer
increas
halflif
dendrim
complex
illustr
highest
rate
regul
vegf
mrna
xenograft
mice
furthermor
tumourinhibit
angiogenyinhibit
activ
also
observ
anoth
studi
xenograft
li
et
al
inorgan
nc
prepar
synthet
inorgan
materi
hard
waterinsolubl
less
biodegrad
toxic
tatiparti
et
al
due
limit
inorgan
nc
less
use
onc
deliv
sirna
molecul
frequent
use
inorgan
nc
mesopor
silica
nanoparticl
differ
metal
np
gold
np
aunp
selenium
np
senp
silver
np
agnp
metal
oxid
np
like
superparamagnet
iron
oxid
nanoparticl
spion
bare
inorgan
nc
less
biocompat
low
sirna
load
capac
onc
reason
nc
mainli
solid
therefor
unabl
encapsul
molecul
molecul
adsorb
molecul
outer
surfac
increas
biocompat
load
capac
outer
surfac
nc
coat
sever
biocompat
biodegrad
natur
synthet
polym
lipid
tabl
use
mesopor
silica
nanoparticl
msn
increas
biomed
pharmaci
field
msnp
spheric
shape
high
surfac
area
tunabl
small
size
biocompat
biodegrad
easili
surfac
function
also
sever
order
porou
structur
surfac
therapeut
hydrophob
drug
bioimag
agent
gene
chemotherapeut
agent
trap
store
pore
fig
due
specif
charact
msn
show
advantag
high
load
effici
control
releas
encapsul
agent
mekaru
et
al
msn
small
size
diamet
rang
nm
therefor
passiv
transport
across
membran
barrier
give
epr
effect
leaki
vasculatur
accumul
tumor
cell
maeda
homogen
monodispers
msn
mostli
synthes
solgel
method
high
load
specif
site
deliveri
anion
sirna
msn
coat
cation
polym
peg
pei
aminetermin
pamam
dendrim
meng
et
al
ngamcherdtrakul
et
al
calcium
phosphat
cap
particl
commonli
use
biocompat
biodegrad
inorgan
carrier
high
load
sirna
cap
compon
also
present
human
bone
cap
particl
sever
demerit
also
obtain
micros
polydispers
nanos
monodispers
cap
np
obtain
precipit
peg
cap
np
shown
toxic
higher
concentr
rnaiinduc
concentr
also
shown
better
control
endogen
vegf
mrna
express
cultur
pancreat
cancer
line
research
synthes
lipidcalciumphosph
coreshel
nanoparticl
lcp
np
microemuls
technolog
improv
system
deliveri
antiluciferas
sirna
type
np
calcium
phosphat
core
surround
cation
lipid
shell
decor
anisamid
ligand
complementari
sigma
receptor
melanoma
cell
surfac
iv
inject
sirna
luciferas
luminesc
signal
metastat
tumor
cell
significantli
diminish
mice
yang
et
al
sever
other
studi
also
done
system
deliveri
sirna
use
cap
np
inorgan
nanoparticl
qiu
et
al
pittella
et
al
last
decad
scientist
research
develop
test
appli
sever
type
metal
gold
silver
selenium
cobalt
nickel
etc
metal
oxid
iron
oxid
silver
oxid
manganes
oxid
etc
np
biomed
applic
initi
au
np
use
drug
deliveri
biomolecular
sens
hypertherm
therapi
howev
current
aunp
also
use
intracellular
gene
deliveri
therapi
due
uniqu
control
optic
properti
easi
alter
surfac
thiolat
molecul
fig
giljohann
et
al
prepar
polyval
sirnagold
nanoparticl
conjug
sirnaaunp
stabl
serum
exhibit
prolong
halflif
knockdown
luciferas
gene
express
free
rna
duplex
giljohann
et
al
sever
way
load
suffici
amount
sirna
au
np
thiol
bondsirna
directli
attach
aunp
surfac
via
goldthiol
rsh
bond
ii
ionic
bondanion
sirna
attach
surfac
cation
aunp
due
electrostat
interact
iii
polym
coat
surfacesirna
adher
aunp
surfac
coat
biocompat
biodegrad
polym
lee
et
al
iron
oxid
np
frequent
use
metal
nanoparticl
numer
biomed
applic
frequent
use
deliv
variou
therapeut
agent
iron
oxid
np
also
known
magnet
nanoparticl
mnp
high
magnet
behaviour
behaviour
use
remotelycontrol
sitespecif
deliveri
sever
therapeut
molecul
drug
gene
appli
extern
magnet
field
fig
mnp
diamet
nm
rang
obtain
two
differ
oxid
statesf
ferric
oxid
hematit
fe
magnetitelodeston
np
diamet
np
nm
show
properti
paramagnet
hysteresi
magnet
loop
particl
neglig
coerciv
aris
infinit
small
energi
barrier
lian
et
al
organ
inorgan
nc
individu
benefit
appli
remov
variou
hurdl
deliv
genet
materi
howev
class
np
limit
inorgan
np
msn
may
stabil
mechan
chemic
imag
properti
accumul
nondegrad
substanc
confer
toxic
side
organ
nc
polym
liposom
micel
biocompat
well
biodegrad
high
encapsul
effici
surfac
within
core
less
stabl
invivo
remov
drawback
type
np
hybrid
nc
best
solut
hybrid
nc
prepar
fusion
organ
inorgan
nc
numer
biocompat
biodegrad
polym
coat
graft
surfac
nc
polym
increas
biocompat
load
tendenc
gene
reduc
toxic
tatiparti
et
al
meanwhil
inorgan
constitu
provid
diagnost
therapeut
properti
therefor
hybrid
nc
benefit
offer
theranost
applic
high
deliveri
effici
sailor
jiho
young
et
al
tabl
convent
therapi
alreadi
appli
treat
sever
deadli
diseas
cancer
tuberculosi
aid
etc
howev
use
quit
limit
due
sever
weak
like
nontarget
deliveri
high
dose
dose
frequenc
give
numer
advers
effect
multidrug
resist
current
gene
therapi
acclaim
revolutionari
option
new
therapi
sirna
deliveri
altern
approach
pursu
activ
excel
safeti
high
rabi
viru
glycoprotein
efficaci
specif
easi
modif
unlimit
therapeut
target
therapeut
efficaci
nake
sirna
reduc
due
system
instabl
reach
target
site
get
rid
hurdl
vital
solut
develop
biocompat
biodegrad
sitespecif
nanos
carrier
everi
nc
benefit
limit
depend
physicochem
composit
offer
flexibl
wide
varieti
effect
agent
base
sirna
organ
nc
polymer
lipidbas
nanoparticl
micel
excel
tendenc
encapsul
therapeut
molecul
nevertheless
unstabl
easili
degrad
within
system
circul
caus
prematur
releas
therapeut
molecul
reach
specif
site
mix
polym
micel
quit
stabl
compar
singl
polym
micel
inorgan
nake
metal
metal
oxid
nc
like
au
np
mnp
stabl
easili
function
spite
advantag
sever
studi
prove
larger
size
higher
concentr
nc
toxic
moreov
nake
nc
also
unstabl
system
deliveri
rapidli
agglomer
blood
plasma
protein
henc
nc
requir
stabil
materi
last
nanocarri
mediat
deliveri
system
better
solut
resolv
issu
relat
potent
system
deliveri
sirna
deliveri
system
also
proven
valu
pass
initi
clinic
phase
